Perioral Dermatitis

Back

Background

Perioral dermatitis (POD) is a chronic papulopustular facial dermatitis. It mostly occurs in women and children.[1] The clinical and histologic features of the perioral dermatitis lesions resemble those of rosacea. Patients require systemic and/or topical treatment and an evaluation of the underlying factors.

See the image below.



View Image

Perioral dermatitis. Courtesy of Professor Raimo Suhonen and DermNet New Zealand (http://www.dermnetnz.org/assets/Uploads/acne/s/pod6.jpg).

Pathophysiology

The etiology of perioral dermatitis (POD) is unknown; however, the long-term use of topical steroids for minor skin alterations of the face often precedes the manifestation of perioral dermatitis. Perioral dermatitis is limited to the skin.

Etiology of Perioral Dermatitis

An underlying cause of the perioral dermatitis (POD) cannot be detected in all patients. The etiology of perioral dermatitis is unknown; however, long-term use of topical steroids for minor skin alterations of the face often precedes the manifestation of the disease. Note the following:

Epidemiology

Frequency

United States

The incidence of perioral dermatitis (POD)  is estimated to be 0.5-1% in industrialized countries, independent of geographic factors.

International

The incidence of perioral dermatitis seems to be lower in less developed countries, but no statistics are available.

Sex

In adults, perioral dermatitis predominantly affects young females, who account for an estimated 90% of the cases. The number of male patients is assumed to be increasing because of changes in their cosmetic habits.

Age

In adults, the vast majority of patients are women aged 20-45 years. Perioral dermatitis also occurs commonly in children.

Prognosis

Perioral dermatitis (POD) is not a life-threatening disease. However, unexpectedly long period of treatment may be required to achieve a cosmetically satisfactory skin condition.

Patient Education

Reassurance and education about possible underlying factors and the time course of the disease are critical. These measures help the patient to cope with the character of the disease and help to minimize the risk of recurrences.

Patients have to be aware that initial deterioration may occur, especially if they previously used a topical steroid.

The use of all topical preparations, including cosmetics, should be avoided except the prescribed medication.

The patient should be advised that remission might not occur for many weeks, despite correct treatment.

History

Subjective symptoms of perioral dermatitis (POD) may consist of a sensation of stinging and burning. Itching is rare.

Often, long-term use of topical steroids for minor or even undiagnosed skin alterations precedes the development of perioral dermatitis.

Perioral dermatitis tends to be chronic.

Physical Examination

Perioral dermatitis (POD) is limited to the skin.

Skin lesions occur as grouped follicular reddish papules, papulovesicles, and papulopustules on an erythematous base with a possible confluent aspect. The papules and pustules have primarily a perioral distribution. Other locations of involvement include the nasolabial fold and lateral portions of the lower eyelids. Vulvar involvement has been reported in young girls affected with perioral dermatitis.

In an extreme variant of the disease called granulomatous perioral dermatitis, granulomatous infiltrates have a yellowish aspect at diascopy. The lesions are confluent in a well-defined plaque delineated by the nasolabial folds and chin.[8]

Complications

Although perioral dermatitis (POD) is limited to the skin and not life threatening, emotional problems may occur because of the character of the facial lesions and the possibly prolonged course of the disease.

An initial rebound effect frequently occurs during the weaning of the steroid. This phenomenon is rare when no underlying cause can be evaluated.

A chronic course is not uncommon.

The development of a lupoid dermal infiltrate is considered to be a feature of the maximal variant of the disease. The diagnosis is made on the basis of the yellowish discoloration after diascopy. This entity is called lupuslike perioral dermatitis.

Scarring may be a problem with the lupoid form of perioral dermatitis.

Laboratory Studies

The diagnosis is made clinically. No laboratory abnormalities can be expected.

Other Tests

In a German study,[12] perioral dermatitis (POD) patients experienced significantly increased transepidermal water loss compared with rosacea patients and a control group, which indicated a skin barrier function disorder. This type of testing is not routinely used.

Histologic Findings

Histologic findings are similar to those of rosacea, but the signs of actinic skin damage are generally less intense and vary according to the patient's age. Thus, a lymphohistiocytic infiltrate with perifollicular localization can be expected in all stages. A marked granulomatous inflammation and, occasionally, perifollicular abscesses may be present when pustules and papules are the dominant clinical findings.

Medical Care

Anti-inflammatory systemic and/or topical therapy similar to that used for rosacea is required. Photodynamic therapy (PDT) has been reported to be helpful for perioral dermatitis (POD),[13] although large studies have not yet been performed.

Topical praziquantel effectively improved symptoms of perioral dermatitis and quality of life in a small vehicle-controlled study.[14]

Treatment should be adapted to the severity and extension of the disease.

Reassurance and education about possible underlying factors and the time course of the disease are critical. These measures help the patient to cope with the disfiguring character of the disease and help to minimize the risk of recurrences.

The use of cosmetics, cleansers, and moisturizers should be avoided during treatment.

In 2014, a treatment algorithm was proposed to assist physicians in finding the appropriate therapy.[15]

Consultations

Consult a dermatologist to evaluate provoking factors and to determine the individualized treatment.[16]

Activity

In general, physical activity is not restricted; however, vasodilation of dermal vessels due to strenuous physical exercise may worsen subjective symptoms.

Prevention

If provoking factors can be determined, they should be avoided.

Long-Term Monitoring

Care includes an assessment of the effectiveness of systemic therapy. Topical therapy should be adapted in accordance to the condition of the skin and the severity of the disease.

Medication Summary

In mild cases, as well as in most children and pregnant women, individualized topical therapy is generally recommended. Antimicrobial agents (eg, metronidazole[6, 17, 18, 19] and erythromycin) are administered in a nongreasy base (eg, gel, lotion, cream). Pimecrolimus cream significantly reduced the Perioral Dermatitis Severity Index[20] (PODSI) compared with vehicle in a randomized, double-blind study in adults.[21] Pimecrolimus cream seems to be most effective in steroid-induced perioral dermatitis.[22] Topical antiacne medications such as adapalene[23] and azelaic acid[24, 25] have been used in open studies. Ointments should be avoided.

In severe forms of perioral dermatitis, systemic treatment with antirosacea drugs is required. The drugs of choice are doxycycline (or tetracycline) and minocycline. In unresponsive and granulomatous forms, oral isotretinoin[26] may be considered. Oral erythromycin can be used in pediatric patients with more severe or refractory involvement.

Zero-therapy is based on the idea that by ceasing use of all topical medications and cosmetics, the underlying causative factor for perioral dermatitis is eliminated. This form of therapy is appropriate in very compliant patients. It may be effective predominantly in cases associated with steroid abuse or when intolerance to cosmetics is suspected.[27, 28]

In every case, an initial worsening of the symptoms may occur with treatment, especially if topical steroids are withdrawn. The patient should be made aware of this complication. In cases of preceding long-term use of topical steroids, steroid weaning with low-dose 0.1-0.5% hydrocortisone cream can be tried initially.

The use of potent topical steroids is strictly contraindicated. However, in some cases, the initial tapering use of a low-potency corticosteroid (eg, hydrocortisone cream) may be appropriate.

Doxycycline (Oracea, Doryx, Vibramycin)

Clinical Context:  Doxycycline is the drug of choice in nonpregnant women. It inhibits protein synthesis and thus bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria. Alternatively, one may use tetracycline in adapted dose.

Minocycline (Dynacin, Minocin, Solodyn)

Clinical Context:  Minocycline is believed to be the most efficacious tetracycline in dermatoses of sebaceous glands. It is used to treat infections caused by susceptible gram-negative and gram-positive organisms, in addition to infections caused by susceptible Chlamydia, Rickettsia, and Mycoplasma species.

Tetracycline

Clinical Context:  Tetracycline inhibits bacterial protein synthesis by binding with 30S and possibly 50S ribosomal subunits. It has anti-inflammatory activity.

Metronidazole (Flagyl)

Clinical Context:  Metronidazole is an imidazole ring-based antibiotic active against various anaerobic bacteria and protozoa. In concentrations of 0.75-2%, it is considered to be the drug of choice for topical treatment of perioral dermatitis. Metronidazole is available in a gel, lotion, or cream.

Erythromycin (E.E.S., Erythrocin, Ery-Tab)

Clinical Context:  Topical erythromycin in concentrations of 2-4% as a gel or cream is an alternative to metronidazole for topical treatment. It inhibits bacterial growth, possibly by blocking dissociation of peptidyl t-RNA from ribosomes, causing RNA-dependent protein synthesis to arrest. It is used to treat staphylococcal and streptococcal infections.

Class Summary

These drugs may have antibacterial and/or anti-inflammatory effects that are responsible for their effectiveness in perioral dermatitis.

Isotretinoin (Amnesteem, Claravis, Sotret)

Clinical Context:  Isotretinoin is an oral agent used to treat serious dermatologic conditions. It is a synthetic 13-cis isomer of naturally occurring tretinoin (trans -retinoic acid). Both agents are structurally related to vitamin A. Isotretinoin decreases sebaceous gland size and sebum production. It may inhibit sebaceous gland differentiation and abnormal keratinization. Isotretinoin is indicated for long-standing and refractory forms of perioral dermatitis. Because of adverse effects, therapy should be prescribed only by a physician familiar with this drug (ie, dermatologist).

A US Food and Drug Administration–mandated registry is now in place for all individuals prescribing, dispensing, or taking isotretinoin. For more information on this registry, see iPLEDGE. This registry aims to further decrease the risk of pregnancy and other unwanted and potentially dangerous adverse effects during a course of isotretinoin therapy.

Class Summary

These agents reduce the size of the sebaceous glands, decrease sebum secretion, and inhibit keratinization.

Pimecrolimus (Elidel)

Clinical Context:  Pimecrolimus is the first nonsteroid cream approved in the United States for mild-to-moderate atopic dermatitis. It is derived from ascomycin, a natural substance produced by the fungus Streptomyces hygroscopicus var ascomyceticus. Pimecrolimus selectively inhibits the production and release of inflammatory cytokines from activated T-cells by binding to cytosolic immunophilin receptor macrophilin-12. The resulting complex inhibits phosphatase calcineurin, thus blocking T-cell activation and cytokine release. Cutaneous atrophy is not observed in clinical trials, a potential advantage over topical corticosteroids.

Class Summary

Pimecrolimus cream controls atopic dermatitis.

What is perioral dermatitis (POD)?What causes perioral dermatitis (POD)?What is the incidence of perioral dermatitis (POD) in the US?What is the international incidence of perioral dermatitis (POD)?Is perioral dermatitis (POD) more common in men or women?What are the age-related demographics for perioral dermatitis (POD)?What is the prognosis of perioral dermatitis (POD)?What educational information should be provided to patients with with perioral dermatitis (POD)?What are the different causes of perioral dermatitis (POD)?What are the common patient complaints of perioral dermatitis (POD)?What is the role of topical steroids in the etiology of perioral dermatitis (POD)?Is perioral dermatitis (POD) chronic or acute?What part of the body is affected by perioral dermatitis (POD)?How are the lesion patterns characterized in perioral dermatitis (POD)?What is granulomatous perioral dermatitis (POD)?What are the complications of perioral dermatitis (POD)?What are the diagnostic considerations for perioral dermatitis (POD)?What are the differential diagnoses for Perioral Dermatitis?Which lab studies are indicated in the workup of perioral dermatitis (POD)?Which tests are used in the workup of perioral dermatitis (POD)?What are the histologic findings in perioral dermatitis (POD)?What are the treatment options for perioral dermatitis (POD)?Is praziquantel an effective treatment for perioral dermatitis (POD)?How is the course of treatment determined in perioral dermatitis (POD)?Why is patient reassurance and education important in the treatment of perioral dermatitis (POD)?Which products should be avoided during the treatment of perioral dermatitis (POD)?Which specialist consultation is indicated in the treatment of perioral dermatitis (POD)?Are activity restrictions indicated in the treatment of perioral dermatitis (POD)?How is perioral dermatitis (POD) prevented?What is included in the long-term monitoring of perioral dermatitis (POD)?Which topical therapies are effective for the treatment of perioral dermatitis (POD)?What are the treatment options for severe forms of perioral dermatitis (POD)?What is zero-therapy and how is it used in the treatment of perioral dermatitis (POD)?Are topical steroids indicated for the treatment of perioral dermatitis (POD)?Which medications in the drug class Antibiotics, Other are used in the treatment of Perioral Dermatitis?Which medications in the drug class Retinoid-Like Agents are used in the treatment of Perioral Dermatitis?Which medications in the drug class Immunomodulators are used in the treatment of Perioral Dermatitis?

Author

Hans J Kammler, MD, PhD, Director and Professor, University Medical Center Bonn, Germany

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Almirall S.A.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

William D James, MD, Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

Disclosure: Received income in an amount equal to or greater than $250 from: Elsevier; WebMD.

Additional Contributors

Andrea Leigh Zaenglein, MD, Professor of Dermatology and Pediatrics, Department of Dermatology, Hershey Medical Center, Pennsylvania State University College of Medicine

Disclosure: Received consulting fee from Galderma for consulting; Received consulting fee from Valeant for consulting; Received consulting fee from Promius for consulting; Received consulting fee from Anacor for consulting; Received grant/research funds from Stiefel for investigator; Received grant/research funds from Astellas for investigator; Received grant/research funds from Ranbaxy for other; Received consulting fee from Ranbaxy for consulting.

References

  1. Kihiczak GG, Cruz MA, Schwartz RA. Periorificial dermatitis in children: an update and description of a child with striking features. Int J Dermatol. 2009 Mar. 48(3):304-6. [View Abstract]
  2. Chen AY, Zirwas MJ. Steroid-induced rosacealike dermatitis: case report and review of the literature. Cutis. 2009 Apr. 83(4):198-204. [View Abstract]
  3. Peralta L, Morais P. Perioral dermatitis -- the role of nasal steroids. Cutan Ocul Toxicol. 2012 Jun. 31(2):160-3. [View Abstract]
  4. Beacham BE, Kurgansky D, Gould WM. Circumoral dermatitis and cheilitis caused by tartar control dentifrices. J Am Acad Dermatol. 1990 Jun. 22(6 Pt 1):1029-32. [View Abstract]
  5. Karincaoglu Y, Bayram N, Aycan O, Esrefoglu M. The clinical importance of demodex folliculorum presenting with nonspecific facial signs and symptoms. J Dermatol. 2004 Aug. 31(8):618-26. [View Abstract]
  6. Abeck D, Geisenfelder B, Brandt O. Physical sunscreens with high sun protection factor may cause perioral dermatitis in children. J Dtsch Dermatol Ges. 2009 Aug. 7(8):701-3. [View Abstract]
  7. Maeda A, Ishiguro N, Kawashima M. The pathogenetic role of rod-shaped bacteria containing intracellular granules in the vellus hairs of a patient with perioral dermatitis: A comparison with perioral corticosteroid-induced rosacea. Australas J Dermatol. 2015 Apr 20. [View Abstract]
  8. Baratli J, Megahed M. [Lupoid perioral dermatitis as a special form of perioral dermatitis : Review of pathogenesis and new therapeutic options.]. Hautarzt. 2013 Nov 9. [View Abstract]
  9. Antille C, Saurat JH, Lübbe J. Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol. 2004 Apr. 140(4):457-60. [View Abstract]
  10. Dirschka T, Tronnier H, Folster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol. 2004 Jun. 150(6):1136-41. [View Abstract]
  11. Lucas CR, Korman NJ, Gilliam AC. Granulomatous periorificial dermatitis: a variant of granulomatous rosacea in children?. J Cutan Med Surg. 2009 Mar-Apr. 13(2):115-8. [View Abstract]
  12. Richey DF, Hopson B. Photodynamic therapy for perioral dermatitis. J Drugs Dermatol. 2006 Feb. 5(2 Suppl):12-6. [View Abstract]
  13. Smith KW. Perioral dermatitis with histopathologic features of granulomatous rosacea: successful treatment with isotretinoin. Cutis. 1990 Nov. 46(5):413-5. [View Abstract]
  14. Bribeche MR, Fedotov VP, Jillella A, Gladichev VV, Pukhalskaya DM. Topical praziquantel as a new treatment for perioral dermatitis: results of a randomized vehicle-controlled pilot study. Clin Exp Dermatol. 2014 Jun. 39 (4):448-53. [View Abstract]
  15. Tempark T, Shwayder TA. Perioral dermatitis: a review of the condition with special attention to treatment options. Am J Clin Dermatol. 2014 Apr. 15 (2):101-13. [View Abstract]
  16. Sharma R, Abrol S, Wani M. Misuse of topical corticosteroids on facial skin. A study of 200 patients. J Dermatol Case Rep. 2017 Mar 31. 11 (1):5-8. [View Abstract]
  17. Miller SR, Shalita AR. Topical metronidazole gel (0.75%) for the treatment of perioral dermatitis in children. J Am Acad Dermatol. 1994 Nov. 31(5 Pt 2):847-8. [View Abstract]
  18. Wollenberg A, Oppel T. Scoring of skin lesions with the perioral dermatitis severity index (PODSI). Acta Derm Venereol. 2006. 86(3):251-2. [View Abstract]
  19. Oppel T, Pavicic T, Kamann S, Brautigam M, Wollenberg A. Pimecrolimus cream (1%) efficacy in perioral dermatitis - results of a randomized, double-blind, vehicle-controlled study in 40 patients. J Eur Acad Dermatol Venereol. 2007 Oct. 21(9):1175-80. [View Abstract]
  20. Jansen T. Perioral dermatitis successfully treated with topical adapalene. J Eur Acad Dermatol Venereol. 2002 Mar. 16(2):175-7. [View Abstract]
  21. Jansen T. Azelaic acid as a new treatment for perioral dermatitis: results from an open study. Br J Dermatol. 2004 Oct. 151(4):933-4. [View Abstract]
  22. Schwarz T, Kreiselmaier I, Bieber T, et al. A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. J Am Acad Dermatol. 2008 Jul. 59(1):34-40. [View Abstract]
  23. Del Rosso JQ. The use of topical azelaic acid for common skin disorders other than inflammatory rosacea. Cutis. 2006 Feb. 77(2 Suppl):22-4. [View Abstract]
  24. Hafeez ZH. Perioral dermatitis: an update. Int J Dermatol. 2003 Jul. 42(7):514-7. [View Abstract]
  25. Katsambas AD, Nicolaidou E. Acne, perioral dermatitis, flushing, and rosacea: unapproved treatments or indications. Clin Dermatol. 2000 Mar-Apr. 18(2):171-6. [View Abstract]
  26. Boeck K, Abeck D, Werfel S, Ring J. Perioral dermatitis in children--clinical presentation, pathogenesis-related factors and response to topical metronidazole. Dermatology. 1997. 195(3):235-8. [View Abstract]
  27. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006 Jan. 54(1):1-15; quiz 16-8. [View Abstract]
  28. Hall CS, Reichenberg J. Evidence based review of perioral dermatitis therapy. G Ital Dermatol Venereol. 2010 Aug. 145(4):433-44. [View Abstract]

Perioral dermatitis. Courtesy of Professor Raimo Suhonen and DermNet New Zealand (http://www.dermnetnz.org/assets/Uploads/acne/s/pod6.jpg).

Perioral dermatitis. Courtesy of Professor Raimo Suhonen and DermNet New Zealand (http://www.dermnetnz.org/assets/Uploads/acne/s/pod6.jpg).